, Singapore
Photo from Envato Elements

China Medical System profit up 3.1% in H1

Revenue increased 10.8% to $715.2m

China Medical System Holdings reported a net profit of $166.5m (RMB931.5m) for the six months ended 30 June 2025, up 3.1% from $161.5m (RMB903.4m) in the same period last year.

Revenue increased 10.8% to $715.2m (RMB4,002m). If all medicines were sold directly by the group, turnover would have risen 8.9% to $834.8m (RMB4,669.6m).

Basic earnings per share grew 4.2% to $0.0695 (RMB0.3892), compared with $0.0667 (RMB0.3734) in H1 2024.

As of 30 June 2025, the group held $617.5m (RMB3,454.1m) in cash and bank balances, with $31.9m (RMB178.6m) in readily realisable bank acceptance bills.

The board declared an interim dividend of $0.0278 per share (RMB0.1555), up 3.2% from $0.0269 (RMB0.1507) in H1 2024.

The board said the solid profit growth reflects CMS’s continued focus on operational efficiency and sustainable expansion in the healthcare sector.
 

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

If you've been wondering whether SBR could work for your company — yes, probably.

A lot of the companies we partner with started as readers. They'd been following our coverage for a while, saw their own customers and competitors in it, and eventually asked the obvious question: could we do something with you? The answer is usually yes. The shape of it depends on what you're trying to do.


The options are broader than most people assume — thought leadership articles, sponsored content, industry summits across Southeast Asia, regional awards programmes, podcasts, and media placements in print and digital. Some partners use one channel; most use a mix. We figure out the right combination by starting with your brief, not with our rate card.


So if the question has been on your mind, here's the easy way to ask it.

We'll tell you honestly whether we can help, and how. It's a better use of everyone's time.